

Prescriber Criteria Form  
Synarel 2026 PA Fax 5802-A v2 010126.docx  
Synarel (nafarelin acetate)  
Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations.  
Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673**. Please contact  
CVS Caremark at **1-866-785-5714** with questions regarding the prior authorization process. When conditions are  
met, we will authorize the coverage of Synarel (nafarelin acetate).

Drug Name:  
Synarel (nafarelin acetate)

<b>Patient Name:</b>		
<b>Patient ID:</b>		
<b>Patient DOB:</b>	<b>Patient Phone:</b>	
<b>Prescriber Name:</b>		
<b>Prescriber Address:</b>		
<b>City:</b>	<b>State:</b>	<b>Zip:</b>
<b>Prescriber Phone:</b>	<b>Prescriber Fax:</b>	
<b>Diagnosis:</b>	<b>ICD Code(s):</b>	

<b>Please circle the appropriate answer for each question.</b>			
1	Does the patient have a diagnosis of central precocious puberty (CPP)? [If no, then skip to question 9.]	Yes	No
2	Is the patient currently receiving the prescribed medication? [If yes, then skip to question 8.]	Yes	No
3	Has the diagnosis of central precocious puberty (CPP) been confirmed by a pubertal response to a gonadotropin releasing hormone (GnRH) agonist test OR a pubertal level of a third generation luteinizing hormone (LH) assay? [If no, then no further questions.]	Yes	No
4	Does the assessment of bone age versus chronological age support the diagnosis of central precocious puberty (CPP)? [If no, then no further questions.]	Yes	No
5	Is the patient female? [If no, then skip to question 7.]	Yes	No
6	Did the onset of secondary sexual characteristics occur prior to eight years of age? [If yes, then skip to question 8.] [If no, then no further questions.]	Yes	No
7	Did the onset of secondary sexual characteristics occur prior to nine years of age? [If no, then no further questions.]	Yes	No

8	Is the patient less than 12 years of age if female or less than 13 years of age if male? [No further questions.]	Yes	No
9	Is the requested drug being prescribed for the management of endometriosis, including pain relief and reduction of endometriotic lesions? [If no, then no further questions.]	Yes	No
10	Is the patient 18 years of age or older? [If no, then no further questions.]	Yes	No
11	Has the patient already received greater than or equal to 6 months of treatment with the requested drug?	Yes	No

Comments:	

By signing this form, I attest that the information provided is accurate and true as of this date and that the documentation supporting this information is available for review if requested by the health plan.	
<b>Prescriber (or Authorized) Signature:</b> _____ <b>Date:</b> _____	